Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression

K Yoshida, S Toden, P Ravindranathan, H Han… - …, 2017 - academic.oup.com
Abstract Development of resistance to chemotherapeutic drugs is a major challenge in the
care of patients with pancreatic ductal adenocarcinoma (PDAC). Acquired resistance to …
被引用次数：204 相关文章

Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.

K Yoshida, S Toden, PR Preethi Ravindranathan… - 2017 - cabidigitallibrary.org
Abstract Development of resistance to chemotherapeutic drugs is a major challenge in the
care of patients with pancreatic ductal adenocarcinoma (PDAC). Acquired resistance to …

Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression

K Yoshida, S Toden, P Ravindranathan… - …, 2017 - pubmed.ncbi.nlm.nih.gov
Development of resistance to chemotherapeutic drugs is a major challenge in the care of
patients with pancreatic ductal adenocarcinoma (PDAC). Acquired resistance to …

Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.

K Yoshida, S Toden, P Ravindranathan… - …, 2017 - search.ebscohost.com
Abstract Development of resistance to chemotherapeutic drugs is a major challenge in the
care of patients with pancreatic ductal adenocarcinoma (PDAC). Acquired resistance to …

Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.

K Yoshida, S Toden, P Ravindranathan, H Han… - …, 2017 - europepmc.org
Abstract Development of resistance to chemotherapeutic drugs is a major challenge in the
care of patients with pancreatic ductal adenocarcinoma (PDAC). Acquired resistance to …
[HTML] nih.gov

[HTML][HTML] Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression

K Yoshida, S Toden, P Ravindranathan, H Han… - …, 2017 - ncbi.nlm.nih.gov
Abstract Development of resistance to chemotherapeutic drugs is a major challenge in the
care of patients with pancreatic ductal adenocarcinoma (PDAC). Acquired resistance to …

[引用][C] Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression

K Yoshida, S Toden, P Ravindranathan, H Han… - Carcinogenesis, 2017 - cir.nii.ac.jp
Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit
EZH2, and the lncRNA PVT1 expression | CiNii Research CiNii 国立情報学研究所 学術情報 …

Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression

K Yoshida, S Toden, P Ravindranathan, H Han… - …, 2017 - academic.oup.com
Abstract Development of resistance to chemotherapeutic drugs is a major challenge in the
care of patients with pancreatic ductal adenocarcinoma (PDAC). Acquired resistance to …

Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.

K Yoshida, S Toden, P Ravindranathan, H Han… - …, 2017 - europepmc.org
Abstract Development of resistance to chemotherapeutic drugs is a major challenge in the
care of patients with pancreatic ductal adenocarcinoma (PDAC). Acquired resistance to …